Aberdeen Group’s US Physical Therapy USPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-291,546
Closed -$33.2M 1072
2021
Q3
$33.2M Buy
291,546
+14,362
+5% +$1.64M 0.07% 253
2021
Q2
$32.2M Buy
277,184
+6,156
+2% +$707K 0.07% 257
2021
Q1
$28.2M Buy
271,028
+5,722
+2% +$712K 0.06% 277
2020
Q4
$32M Sell
265,306
-71,958
-21% -$7.26M 0.08% 230
2020
Q3
$29.3M Buy
337,264
+14,759
+5% +$1.27M 0.08% 200
2020
Q2
$26.1M Buy
322,505
+61,945
+24% +$4.52M 0.07% 245
2020
Q1
$18M Buy
260,560
+24,191
+10% +$2.55M 0.06% 280
2019
Q4
$27.1M Sell
236,369
-785
-0.3% -$97.7K 0.07% 276
2019
Q3
$31M Sell
237,154
-50,698
-18% -$6.6M 0.08% 227
2019
Q2
$35.3M Sell
287,852
-39,854
-12% -$4.58M 0.08% 242
2019
Q1
$34.4M Buy
327,706
+2,886
+0.9% +$310K 0.07% 249
2018
Q4
$32.7M Sell
324,820
-36,687
-10% -$4.07M 0.08% 234
2018
Q3
$42.9M Sell
361,507
-112,815
-24% -$12.7M 0.08% 237
2018
Q2
$45.5M Sell
474,322
-27,308
-5% -$2.53M 0.09% 220
2018
Q1
$40.8M Sell
501,630
-73,960
-13% -$5.73M 0.08% 237
2017
Q4
$41.6M Sell
575,590
-166,156
-22% -$11.3M 0.08% 232
2017
Q3
$45.6M Buy
+741,746
New +$45.2M 0.08% 222

Other funds holding USPH

Aberdeen Group's USPH Position: Q4 2021 in Review

Aberdeen Group sold out of US Physical Therapy (USPH) in Q4 2021, closing a stake of 291,546 shares — an estimated $33.2M sold.

Aberdeen Group first reported a position in USPH in Q3 2017 and held it in 17 quarters. The position peaked at $45.6M in Q3 2017. 210 funds tracked by Wall St. Rank hold USPH as of Q4 2021.

  • Aberdeen Group reported no remaining US Physical Therapy position as of Q4 2021 after selling out during the quarter.
  • Aberdeen Group sold 291,546 US Physical Therapy shares in Q4 2021, an estimated $33.2M.
  • Aberdeen Group first reported a position in US Physical Therapy in Q3 2017 and held it in 17 quarters.
  • Aberdeen Group's US Physical Therapy position peaked at $45.6M in Q3 2017.
  • 210 funds tracked by Wall St. Rank held US Physical Therapy as of Q4 2021.

Based on Aberdeen Group's 13F filing for Q4 2021, filed 8 Feb 2022.